|Awarded On||August 18, 2021|
|Title||Targeting Mitochondrial NAD+ in Leukemias|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas at Austin|
|Principal Investigator/Program Director||Xiaolu Cambronne|
*Pending contract negotiation
My group recently discovered a new protein called SLC25A51 that controls how all human cells harness energy through metabolic pathways in the mitochondria. One of the biggest challenges in acute myeloid leukemia is that most patients relapse in less than five years, and so there is a need to identify new therapeutic targets. Intriguingly, this type of cancer requires a metabolism that is directly controlled by SLC25A51 to survive. We propose that blocking the activity of SLC25A51 could advantageously target and exploit a unique vulnerability in leukemic cells. We will determine whether block of SLC25A51 stops the expansion of the cancer, as well as optimize a test we developed to identify co...